MDSpire - Summary
From the Journals

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

“For women with low-risk DCIS, these interim results are reassuring. There is currently no indication that active surveillance leads to worse early outcomes compared with immediate surgery. It’s impor...

Share

The LORD trial, presented at the 15th European Breast Cancer Conference, evaluates the safety of active surveillance for low-risk ductal carcinoma in situ (DCIS). Conducted by Dr. Jelle Wesseling from the Netherlands, the trial involved 1,423 patients monitored over two years. Early results suggest that monitoring does not worsen outcomes compared to immediate surgery, with only 6% of patients on active surveillance developing invasive breast cancer compared to 9% in the surgery group. The trial aims to explore if overtreatment for DCIS can be reduced without increasing risks for patients.

Original Source(s)

Early Results From a Trial of Active Surveillance for Low-Risk DCIS are ‘Reassuring,’ Say Researchers

  • by The ASCO Post Staff

  • April 1, 2026

Related Content

Could Mass Spec Overcome the CAR T Solid Tumor Barrier?

Joey Sheff explains how proteomics is revealing targets, guiding CAR design, and predicting function in solid tumors.

  • April 1, 2026

  • 8 min
From One Stem Cell to Millions of Cancer Killers

A three-step engineering strategy generates vast numbers of potent NK immune cells – potentially slashing the cost and scaling of cancer immunotherapy

  • April 1, 2026

  • 1 min
AI-Driven Multiagent System for Guiding First-Line Immunotherapy for NSCLC

An artificial intelligence (AI) multiagent system demonstrated correct and complete reasoning in determining the use of immunotherapy for patients with non–small cell lung cancer (NSCLC) in the first-...